Lehtonen L A, Eskola J T, Gordin A, Erkko M K, Räihä I J, Lehtonen A A
Department of Medical Microbiology, University of Turku, Finland.
J Clin Lab Immunol. 1989 Oct;30(2):75-80.
Calcium channel blocking drugs are widely used in the treatment of cardiovascular diseases. In vitro these drugs have been shown to block mitogen-induced lymphocyte proliferation. Their possible immunosuppressive effect has been tested especially in combination with cyclosporine A. In the present work, the effect of the calcium channel blocking drug verapamil on immune functions of cardiovascular patients was studied. The changes in leukocyte subpopulations, mitogenic responses and immunoglobulin production were determined during a three-month therapy. A significant increase in suppressor/cytotoxic cell number was detected and a decrease in the CD4/CD8 ratio, although the values were still within normal range. The responses to T and B cell mitogens remained unchanged. No significant decrease could be detected in immunoglobulin production either, despite minor changes in IgM. Our results indicate that the immunologic effects of verapamil at therapeutic doses are of little clinical significance.
钙通道阻滞剂广泛应用于心血管疾病的治疗。在体外实验中,这些药物已被证明可阻断有丝分裂原诱导的淋巴细胞增殖。它们可能的免疫抑制作用尤其与环孢素A联合进行了测试。在本研究中,研究了钙通道阻滞剂维拉帕米对心血管疾病患者免疫功能的影响。在为期三个月的治疗期间,测定了白细胞亚群、有丝分裂原反应和免疫球蛋白产生的变化。检测到抑制性/细胞毒性细胞数量显著增加,CD4/CD8比值降低,尽管这些值仍在正常范围内。对T和B细胞有丝分裂原的反应保持不变。尽管IgM有轻微变化,但免疫球蛋白产生也未检测到显著下降。我们的结果表明,治疗剂量的维拉帕米的免疫学效应临床意义不大。